IL285146B - Methods for purifying proteins involving fc - Google Patents

Methods for purifying proteins involving fc

Info

Publication number
IL285146B
IL285146B IL285146A IL28514621A IL285146B IL 285146 B IL285146 B IL 285146B IL 285146 A IL285146 A IL 285146A IL 28514621 A IL28514621 A IL 28514621A IL 285146 B IL285146 B IL 285146B
Authority
IL
Israel
Prior art keywords
protein
antibodies
temperature
amino acid
mobile phase
Prior art date
Application number
IL285146A
Other languages
English (en)
Hebrew (he)
Other versions
IL285146A (en
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL285146A publication Critical patent/IL285146A/en
Publication of IL285146B publication Critical patent/IL285146B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Storage Device Security (AREA)
IL285146A 2016-07-22 2017-07-21 Methods for purifying proteins involving fc IL285146B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662365943P 2016-07-22 2016-07-22
PCT/US2017/043384 WO2018018011A2 (en) 2016-07-22 2017-07-21 Methods of purifying fc-containing proteins

Publications (2)

Publication Number Publication Date
IL285146A IL285146A (en) 2021-08-31
IL285146B true IL285146B (en) 2022-09-01

Family

ID=59656168

Family Applications (2)

Application Number Title Priority Date Filing Date
IL285146A IL285146B (en) 2016-07-22 2017-07-21 Methods for purifying proteins involving fc
IL264375A IL264375B (en) 2016-07-22 2019-01-21 Methods of purifying fc-containing proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL264375A IL264375B (en) 2016-07-22 2019-01-21 Methods of purifying fc-containing proteins

Country Status (12)

Country Link
US (1) US11312745B2 (enExample)
EP (1) EP3487867A2 (enExample)
JP (2) JP7092744B2 (enExample)
KR (2) KR102579850B1 (enExample)
CN (2) CN109563125B (enExample)
AU (2) AU2017298984B2 (enExample)
CA (2) CA3218290A1 (enExample)
IL (2) IL285146B (enExample)
MA (1) MA45721A (enExample)
MX (2) MX2019000903A (enExample)
SG (1) SG11201900573UA (enExample)
WO (1) WO2018018011A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022501357A (ja) * 2018-09-21 2022-01-06 テネオバイオ， インコーポレイテッド ヘテロ二量体多重特異性抗体を精製するための方法
EP3863670A1 (en) * 2018-10-11 2021-08-18 Amgen Inc. Downstream processing of bispecific antibody constructs
JP2022517338A (ja) * 2019-01-16 2022-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗体の断片化を特定及び定量する方法及びシステム
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN110724204B (zh) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Fc融合蛋白的纯化方法
CN112881675A (zh) * 2019-11-29 2021-06-01 广东菲鹏生物有限公司 IgM抗体检测稀释液
US12428470B2 (en) 2020-04-09 2025-09-30 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
EP4213958A1 (en) * 2020-09-16 2023-07-26 Waters Technologies Corporation Improved size exclusion chromatography utilizing low concentration amino acids in size exclusion chromatography mobile phase
AU2022369694B2 (en) * 2021-10-19 2025-10-09 Alteogen, Inc Method for purifying fusion protein having igg fc domain
CN113980092B (zh) * 2021-12-09 2024-05-14 上海药明生物技术有限公司 一种蛋白质亲和纯化方法
CN116165290B (zh) * 2021-12-17 2025-06-27 复旦大学 一种抗体药物研发流程中工程细胞株的筛选方法
CN116271982B (zh) * 2022-11-30 2024-01-09 杭州广科安德生物科技有限公司 一种血液高丰度蛋白免疫亲和柱的再生方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143199A1 (ja) * 2007-05-21 2008-11-27 Nomadic Bioscience Co., Ltd. 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法
WO2014081955A1 (en) * 2012-11-21 2014-05-30 Amgen Inc. Heterodimeric immunoglobulins

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
EP1071769A1 (en) * 1998-04-16 2001-01-31 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
MX2007004437A (es) * 2004-10-22 2007-06-20 Amgen Inc Metodos para el repliegue de anticuerpos recombinantes.
ES2402650T3 (es) * 2005-06-17 2013-05-07 Janssen Alzheimer Immunotherapy Métodos de purificación de anticuerpos anti A beta
EP1994054A4 (en) * 2006-01-06 2012-11-07 Amgen Inc METHODS AND SYSTEMS FOR ISOLATING TARGET MOLECULES OF COMPLEX COLUMN CHROMATOGRAPHY SOLUTIONS USING ELEMENTS CONTAINING ORGANIC SOLVENTS
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
US10982250B2 (en) * 2006-09-18 2021-04-20 Genentech, Inc. Methods of protein production
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
MX2011001696A (es) * 2008-08-14 2011-03-25 Merck Sharp & Dohme Metodos para purificar anticuerpos usando cromatografia de afinidad con proteina a.
SG176963A1 (en) * 2009-06-22 2012-02-28 Amgen Inc Refolding proteins using a chemically controlled redox state
WO2010151688A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
US20120302737A1 (en) 2009-09-16 2012-11-29 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
CN102382190B (zh) * 2010-09-01 2014-04-09 山东新时代药业有限公司 分离和去除TNFR-Fc融合蛋白中寡聚体的方法
EP2657254A4 (en) 2010-12-24 2014-01-08 Asahi Kasei Medical Co Ltd PROCESS FOR IMMOBILIZING THE TEMPERATURE-REACTIVE PROTEIN A
AU2012282960A1 (en) 2011-07-08 2014-01-16 Merck Sharp & Dohme Corp. Method for purifying Fc-fusion protein
EP2831096B1 (en) 2012-03-28 2020-04-29 GE Healthcare BioProcess R&D AB Affinity chromatography matrix
JP6253584B2 (ja) 2012-08-27 2017-12-27 旭化成メディカル株式会社 温度応答性クロマトグラフィーによる抗体の精製方法
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
PE20160724A1 (es) * 2013-11-04 2016-08-04 Glenmark Pharmaceuticals Sa Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143199A1 (ja) * 2007-05-21 2008-11-27 Nomadic Bioscience Co., Ltd. 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法
US20100168395A1 (en) * 2007-05-21 2010-07-01 Nomadic Bioscience Co., Ltd. Novel polypeptide, an affinity chromatography material, and a method for separating and/or purifying immunoglobulin
WO2014081955A1 (en) * 2012-11-21 2014-05-30 Amgen Inc. Heterodimeric immunoglobulins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKALUOMA K ET AL,, LYSYL HYDROXYLASE 2 IS A SPECIFIC TELOPEPTIDE HYDROXYLASE, WHILE ALL THREE ISOENZYMES HYDROXYLATE COLLAGENOUS SEQUENCES, 1 June 2007 (2007-06-01) *

Also Published As

Publication number Publication date
IL264375A (en) 2019-02-28
CN109563125B (zh) 2022-08-09
AU2023222915A1 (en) 2023-09-21
AU2017298984B2 (en) 2023-08-31
CN109563125A (zh) 2019-04-02
WO2018018011A2 (en) 2018-01-25
JP2019528255A (ja) 2019-10-10
EP3487867A2 (en) 2019-05-29
JP7092744B2 (ja) 2022-06-28
IL285146A (en) 2021-08-31
MX2023006291A (es) 2023-06-13
US20190127418A1 (en) 2019-05-02
AU2017298984A1 (en) 2019-02-07
MA45721A (fr) 2019-05-29
CA3218290A1 (en) 2018-01-25
WO2018018011A3 (en) 2018-03-01
SG11201900573UA (en) 2019-02-27
JP7411020B2 (ja) 2024-01-10
KR102435801B1 (ko) 2022-08-25
US11312745B2 (en) 2022-04-26
JP2022120138A (ja) 2022-08-17
CN115925780B (zh) 2025-11-04
KR102579850B1 (ko) 2023-09-18
IL264375B (en) 2021-09-30
CN115925780A (zh) 2023-04-07
KR20190037247A (ko) 2019-04-05
KR20220120716A (ko) 2022-08-30
CA3031469A1 (en) 2018-01-25
CA3031469C (en) 2025-11-18
MX2019000903A (es) 2019-05-15

Similar Documents

Publication Publication Date Title
IL285146B (en) Methods for purifying proteins involving fc
US20220289832A1 (en) Protein purification
US9249182B2 (en) Purification of antibodies using hydrophobic interaction chromatography
JP5567691B2 (ja) Ｆｃ含有タンパク質を精製するためのクロマトグラフィー法
WO2013158279A1 (en) Protein purification methods to reduce acidic species
CA3031028A1 (en) Affinity chromatography wash buffer
TW201522365A (zh) 純化抗體的方法
US20200165295A1 (en) Method for purifying anti-il-6 receptor antibodies
JP2023548826A (ja) 加水分解酵素活性速度が低下した医薬組成物を得るための精製プラットフォーム
HK1184467A (en) Protein purification